‘Four years into the pandemic and despite millions missing, there is still no curative treatment for long Covid,’ she wrote.

#LongCOVID

Johanna Köb, the head of responsible investment at Zurich Insurance Company, announced her resignation due to long COVID.

#LongCOVID #PandemicIsNotOver

Source: citywire.com/ch/news/zurich…

🔸6,408 aged care COVID deaths since beginning of pandemic

🔸686 reported deaths in 2020
🔸226 reported deaths in 2021
🔸3,855 reported deaths in 2022
🔸1,359 reported deaths in 2023
🔸282 reported deaths in 2024

Anika Wells MP Anthony Albanese #Nobodyleftbehind

health.gov.au/resources/publ…

A bit late, but here's last weeks report.

COVID-19 outbreaks in Australian residential aged care facilities: 18 April 2024

🔹Active cases: 1,584 (+411)
🔹Active outbreaks: 216 (+15)
🔹Residents: 1,137 (+298)
🔹Staff: 447 (+113)
🔹Reported deaths in 2024: 282 (+10)

Anika Wells MP

I suppose PECKER SCREWS TRUMP wouldn’t work as a headline?

What are we doing to test / safeguard Australian dairy supply chain Mark Butler MP Senator Murray Watt ?

Link
washingtonpost.com/health/2024/04…
by LenaSun Dan Diamond Rachel Roubein Post Health/Science The Washington Post

This isn't good, folks.
I'm not worried about H5N1 transmission to humans (yet) but the Dept. of Agriculture pathetic lack of transparency, how long it took for the genomes to be released, lack of testing asymptomatic cattle......
All detracts from 'confidence'

Tim Anthony Albanese Pandemic is over??? WOW!!! Pandemic is not over because I still know of people catching COVID. And because they have to earn, they have to work. Why? YOU REMOVED ALL MITIGATIONS. Your legacy prime minister, is that you are creating an extremely sick nation. Like Rishi Sunak

Current results do underscore the challenge posed by the continuously evolving SARS-CoV-2 JN.1 lineages and support the consideration of switching the focus of future SARS-CoV-2 vaccine updates to the JN.1 lineage.

We have also isolated and expressed mAbs from these cohorts to compare the humoral immune response landscape at the monoclonal antibody level of XBB and JN.1 exposure. Subsequent studies regarding the mAbs' epitope distribution and escaping mutations will soon be updated.
(7/7)

Additionally, we found that JN.1+F456L and FLiRT showed equal ACE2 binding affinity compared to JN.1, and JN.1.23, which carries a Y453F mutation, exhibits greatly enhanced ACE2 binding. Acquisition of more immune-evasive mutations should be closely monitored for JN.1.23.
(6/7)

KP.3 (JN.1+F456L+Q493E) is the most immune evasive variant we found and is also the fastest-growing JN.1 sublineage. The additional F456L and Q493E mutation allows KP.3 to evade a substantial proportion of JN.1-effective mAbs, especially Class 1 antibodies.
(5/7)

We then compared the immunogenicity of XBB and JN.1 infections in those who had been vaccinated and exposed to Omicron before (Major population). As expected, JN.1 exposure clearly induces higher neutralization titers against emerging mutants, such as FLiRT and KP.3.
(4/7)

We first compared the antibody response of XBB and JN.1 infection in SARS-CoV-2 naive individuals (people who weren't vaccinated and haven't been infected). Similar to naive mice, we found that XBB and JN.1 lineages are also antigenic distinct in naive humans.
(3/7)

Since JN.1 lineages have replaced XBB lineages and JN.1 subvariants are continuously gaining immune-evasive mutations, such as R346T, F456L, R346T+F456L (FLiRT), and F456L+Q493E (KP.3), it's time to evaluate whether we need to switch SARS-CoV-2 vaccine antigen to JN.1.
(2/7)

New study. We compared the immune response of XBB and JN.1 in human infections to evaluate the necessity for #SARSCOV2 vaccine updates
Results:
JN.1 exposure induces higher neutralization against emerging mutants, including FLiRT (JN.1+346T+456L) and KP.3
biorxiv.org/content/10.110…

We've been wondering how well the current XBB.1.5 booster shots hold up vs JN.1 and its FLiRT variant descendants like KP.3. The answer: not well.

Also protecting vs influenza A in mouse model (Figure).
Unanticipated results for an antibiotic vs upper respiratory virus infections, deserving further clinical trial assessment